Original article by Maria Bervanakis
Herald Sun – Page: Online : 22-Dec-21

The European Union has approved the use of Novavax’s protein-based COVID-19 vaccine for people aged 18+. Protein-based vaccines have been safely used for decades, which may increase the vaccine take-up rate among people who have been hesitant about getting an mRNA-based vaccine like those of Pfizer and Moderna. Clinical trials have shown that the Novavax vaccine has an efficacy rate of around 90 per cent, with only mild or moderate side effects. The Australian government has ordered 51 million doses of the vaccine, which has yet to be approved by the Therapeutic Goods Administration.

CORPORATES
NOVAVAX INCORPORATED, AUSTRALIA. THERAPEUTIC GOODS ADMINISTRATION